According to the CDC, obesity affects roughly two in five Americans aged 60 and older, putting this population at greater risk for cardiovascular and metabolic diseases and a decreased quality of…
Found Health has become the latest telehealth company to offer a microdosing program with weight loss jabs, despite an absence of peer-reviewed scientific evidence that shows microdosing GLP-1RA…
AACE released a new consensus update to its Adiposity Based Chronic Disease (ABCD) Algorithm, enhancing the 2016 guidance with a stronger focus on complication centric, person centered care. Rather…
A new review published in Otolaryngology-Head and Neck Surgery reports that individuals with type 2 diabetes face a significantly elevated risk of hearing loss, particularly at higher…
According to new research, people with prediabetes who lower blood sugar to normal levels cut their heart disease risk in half. AACE President Scott D. Isaacs, MD, FACP, FACE, highlights that…
Following FDA approval of the first oral GLP-1 for obesity, AACE President Scott D. Isaacs, MD, FACP, FACE, called the Wegovy pill one of the most important developments in endocrinology in 2025,…
In a Medscape review on type 2 diabetes remission, AACE President Scott D. Isaacs, MD, FACP, FACE, emphasized that remission is not the same as reversal and highlighted growing evidence that…
The long‑awaited results of SURPASS‑CVOT were recently published in the New England Journal of Medicine, marking a major advance in the evidence base for incretin‑based therapy for patients…
The weight loss medication Wegovy is now available as a pill. In an NPR report, AACE Past President Scott D. Isaacs, MD, FACP, FACE, emphasizes the importance of careful patient education, noting…
By: Karl Nadolsky, DO, FACE
Published July 2020
The loudest voices expressing the most extreme recommendations often get the most attention. So in the world of…